FREMONT, Calif., March 7 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that Andrew Guggenhime will join as
Senior Vice President and Chief Financial Officer effective April 3.
Guggenhime will join the company's senior management team reporting
directly to Chief Executive Officer Mark McDade, and will be responsible for
all financial and information technology operations of the company.
Guggenhime joins PDL BioPharma from Neoforma, Inc. where he had been CFO
since October 2000. In this role, he was responsible for the accounting,
finance, financial planning and analysis, investor relations, legal and
facilities departments. He was previously Vice President of Corporate
Development, managing Neoforma's corporate development, business development,
international and strategic efforts.
Prior to joining Neoforma in early 2000, Guggenhime was a Vice President
in the Healthcare Investment Banking group of Merrill Lynch & Co., where he
specialized in working with healthcare services firms and healthcare Internet
companies on a variety of transactions, including mergers and acquisitions,
initial public offerings, add-on equity offerings and debt offerings.
Previously, he worked at Wells Fargo & Company in a number of capacities.
Guggenhime earned a Bachelor of Arts degree in international politics and
economics from Middlebury College and a Master of Management degree from the
J.L. Kellogg Graduate School of Management at Northwestern University.
"Andrew has the commercial, management and financial experience that PDL
BioPharma requires in the CFO role as we focus on growth and solidify our
position as a commercial biopharmaceutical company," said Mark McDade, Chief
Executive Officer, PDL BioPharma. "We are delighted that he will join the
company during an exciting time, as we create value from our diverse stream of
product and royalty revenues, and advance our robust pipeline of six acute
care focused products."
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering,
developing and commercializing innovative therapies for severe or life
threatening illnesses. The company currently markets and sells a portfolio of
leading products in the acute-care hospital setting in the United States and
Canada and generates royalties through licensing agreements with top-tier
biotechnology and pharmaceutical companies based on its pioneering humanized
antibody technology. Currently, PDL BioPharma's diverse late-stage product
pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical
development for hepatorenal syndrome, inflammation and autoimmune diseases,
cardiovascular disorders, and cancer. For more information, please see our
website at http://www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks
of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, or ami.knoefler@pdl.com, or Jim Goff,
Investor Relations, +1-510-574-1421, or james.goff@pdl.com, both
of PDL BioPharma
|
